Curcumin-Loaded PLGA Nanoparticles: A Novel Strategy for Cognitive Enhancement and Neurogenesis in Alzheimer’s Disease

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

Neurodegenerative disorders affect an estimated 1.5 billion individuals worldwide. A central pathological feature of these conditions is neuroinflammation, which disrupts the blood–brain barrier (BBB) and promotes leukocyte infiltration. Although leukocytes are protective immune cells, their abnormal entry into the central nervous system contributes to tissue damage and disease progression. In Alzheimer’s disease (AD), misfolded proteins such as amyloid-beta (Aβ) stimulate neuroinflammatory cascades, further amplifying neuronal injury.

Excessive release of inflammatory mediators such as IL-1β, IL-6, IL-23, and TNF-α exacerbates neuronal death. In parallel, the body relies on protective mechanisms, such as the heat shock response, to counteract cellular stress. Heat shock proteins (HSPs), encoded by vitagenes, play a pivotal role in maintaining redox balance, protein folding, and neuronal survival. Disruption of this protective system is strongly implicated in the pathogenesis of AD.

Pathophysiological Features of Alzheimer’s Disease

Alzheimer’s disease is characterized by protein misfolding, synaptic dysfunction, oxidative stress, impaired homeostasis, and progressive neuronal loss. These pathological processes alter the expression and activity of protective vitagenes, leading to a decline in neuronal resilience. Polyphenols, such as curcumin, have demonstrated the capacity to activate the heat shock response and stimulate HSP expression, thereby supporting neuronal survival pathways.

Curcumin as a Therapeutic Candidate

Curcumin, a hydrophobic polyphenol, exhibits diverse pharmacological properties including anti-inflammatory, antioxidant, neuroprotective, and anti-amyloid effects. It downregulates pro-inflammatory cytokines and mitigates oxidative stress, reducing both neuroinflammation and protein aggregation. However, curcumin’s poor bioavailability and limited brain penetration have restricted its clinical utility.

Nanoparticle-Based Drug Delivery Approach

To address these challenges, researchers have developed poly(lactic-co-glycolic acid) (PLGA) nanoparticles as a delivery system for curcumin. PLGA is biocompatible, biodegradable, and approved for medical use. Curcumin-loaded PLGA nanoparticles (Cur-PLGA-NPs) exhibit enhanced solubility, improved circulation time, and effective BBB penetration. Upon release in the brain, curcumin suppresses inflammatory pathways, inhibits protein aggregation, and promotes neuronal repair.

Therapeutic Mechanisms of Curcumin-Loaded PLGA Nanoparticles

• Reduction of misfolded protein accumulation: Cur-PLGA-NPs inhibit aggregation of amyloid-beta and tau proteins.
• Attenuation of neuroinflammation: Downregulation of cytokines decreases leukocyte infiltration and neuronal injury.
• Neuroprotection and neuroplasticity: Enhances neuronal differentiation, self-renewal, and synaptic repair.
• Activation of stress response pathways: Stimulates HSP expression via vitagene signaling.
• Cognitive improvement: Demonstrated reversal of memory and learning deficits in preclinical AD models.

Preclinical and Translational Findings

In vivo studies have shown that Cur-PLGA-NPs significantly improve cognitive performance and reduce pathological hallmarks of AD compared to bulk curcumin. These nanoparticles demonstrate superior ability to cross the BBB and maintain stability in systemic circulation. Additionally, evidence suggests therapeutic potential beyond AD, including Parkinson’s disease, multiple sclerosis, Huntington’s disease, and epilepsy, where similar neuroinflammatory and protein misfolding processes are observed.

Clinical Implications and Future Directions

Curcumin-loaded nanoparticles offer a safe, stable, and effective therapeutic option for neurodegenerative disorders. Current clinical trials are evaluating the safety and efficacy of Cur-PLGA-NPs in humans, though most data to date derive from animal models. If successful, this approach could overcome long-standing limitations in AD therapy by combining targeted delivery, improved bioavailability, and multi-pathway neuroprotection.

Summary of Therapeutic Benefits

• Inhibits amyloid-beta and tau aggregation
• Enhances memory and learning capacity
• Prolongs systemic circulation and bioavailability
• Penetrates the blood–brain barrier effectively
• Reduces neuronal apoptosis
• Dramatically decreases neuroinflammation
• Stimulates neuroprotection and plasticity
• Supports heat shock protein pathways
• Suppresses immune cell infiltration

REFERENCES

1. Huang, N., Lu, S., Liu, X. G., Zhu, J., Wang, Y. J., & Liu, R. T. (2017). PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s disease mice. Oncotarget, 8(46), 81001.
2. Lin, Y. W., Fang, C. H., Yang, C. Y., Liang, Y. J., & Lin, F. H. (2022). Investigating a curcumin-Loaded PLGA-PEG-PLGA thermo-sensitive hydrogel for the prevention of Alzheimer’s disease. Antioxidants, 11(4), 727.
3. Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., … & Kumar, D. S. (2012). Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease.PLoS one, 7(3), e32616.
4. Neurogenesis, P. I. A. Curcumin-Loaded Nanoparticles.
5. Ray, B., Bisht, S., Maitra, A., Maitra, A., & Lahiri, D. K. (2011). Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: implications for Alzheimer’s disease. Journal of Alzheimer’s disease, 23(1), 61.
6. Zeng, H., Xu, L., Zou, Y., & Wang, S. (2023). The impacts of curcumin on learning memory function in Alzheimer’s disease under the poly lactic-co-glycolic acid nanoparticle drug carrier. Applied Nanoscience, 13(5), 3483-3491.